Prostate Cancer News on BioPortfolio

Midlife PSA Predicts Aggressive Prostate Cancer in Black Men

THURSDAY Oct. 11 2018 Midlife levels of prostatespecific antigen PSA strongly predict future development of aggressive prostate cancer among black men according to a study published online Sept. 17 in European Urology.Mark A. Preston...

Janssen to showcase robust oncology portfolio at ESMO 2018

Abstracts include clinical updates across solid tumor targeted therapies Quality of life outcomes from Phase 3 SPARTAN clinical trial of apalutamide in nonmetastatic castrationresistant prostate cancer ...

Corcept Therapeutics Picks Up Speed NearTerm Clinical Milestones Ahead

On Monday October 1 2018 Corcept Therapeutics announced that relacorilant received an orphan designation from the FDA for treating pancreatic cancer. This article examines the following1. A primer on orphan drugs and orphan oncology. 2. A new cancer trial ...

Corcept Therapeutics Picks Up Speed New Clinical Trials Ahead

On Monday October 1 2018 Corcept Therapeutics announced that relacorilant received an orphan designation from the FDA for treating pancreatic cancer. This article examines the following1. A primer on orphan drugs and orphan oncology. 2. A new cancer trial ...

Pages